文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

分子吸附再循环系统在急性肝衰竭中的应用:多中心倾向评分匹配研究结果

Use of the Molecular Adsorbent Recirculating System in Acute Liver Failure: Results of a Multicenter Propensity Score-Matched Study.
PubMed 文献 · Crit Care Med · 2022-01-01
一句话结论倾向评分匹配的回顾性队列显示,分子吸附再循环系统治疗与急性肝衰竭患者21天无移植生存率升高相关(OR 1.90,95%CI 1.07-3.39)。

该多中心倾向评分匹配回顾性队列纳入三家北美肝移植中心的104例接受分子吸附再循环系统治疗的急性肝衰竭患者,按4:1匹配美国急性肝衰竭研究组注册库的416例标准内科治疗对照。多变量条件logistic回归校正病因、年龄、升压药支持、INR、King's College标准及倾向评分后,分子吸附再循环系统与21天无移植生存率升高显著相关(OR 1.90,95%CI 1.07-3.39,P=0.030),多项敏感性分析结果一致。对乙酰氨基酚亚组(n=51)治疗后平均动脉压、肌酐、乳酸和血氨均显著改善;非对乙酰氨基酚亚组(n=53)胆红素、肌酐和血氨显著改善。

要点

  • 接受分子吸附再循环系统治疗的急性肝衰竭患者21天无移植生存率高于标准内科治疗对照(OR 1.90,95%CI 1.07-3.39,P=0.030),校正病因、年龄、升压药、INR、King's College标准及倾向评分。
  • 敏感性分析中该关联保持一致:仅校正病因和倾向评分时OR 1.86(95%CI 1.05-3.31,P=0.033),进一步校正机械通气和3/4级肝性脑病后OR 1.91(95%CI 1.07-3.41,P=0.029)。
  • 对乙酰氨基酚相关急性肝衰竭亚组(n=51)分子吸附再循环系统治疗后平均动脉压(92.0 vs 78.0 mm Hg)、肌酐(77.0 vs 128.2 µmol/L)、乳酸(2.3 vs 4.3 mmol/L)、血氨(98.0 vs 136.0 µmol/L)均显著改善(P≤0.002)。
  • 非对乙酰氨基酚急性肝衰竭亚组(n=53)治疗后胆红素(205.2 vs 251.4 µmol/L)、肌酐(83.1 vs 133.5 µmol/L)、血氨(111.5 vs 140.0 µmol/L)显著改善(P≤0.022)。
  • 该研究为回顾性倾向评分匹配队列,非随机对照,分子吸附再循环系统与生存的关联不能等同于因果获益。

适用人群与场景

  • 三家北美肝移植中心2009年1月至2019年期间接受分子吸附再循环系统治疗的急性肝衰竭患者(n=104),对照来自美国急性肝衰竭研究组注册库。
  • 匹配后人群包括对乙酰氨基酚相关急性肝衰竭248例和非对乙酰氨基酚急性肝衰竭272例。
  • 原文未提及具体纳入/排除标准及急诊/ICU/院前场景。

诊断标准与关键阈值

  • 原文未提及分子吸附再循环系统的启动或停止阈值。
  • 研究校正变量包括King's College Criteria,但原文未给出具体评分界值。

处置流程与药物剂量

  • 原文未提及分子吸附再循环系统的具体治疗剂量、血流速、疗程或抗凝方案。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心倾向评分匹配回顾性队列分析;分子吸附再循环系统组104例按4:1匹配416例标准内科治疗对照。
  • 主要终点:21天无移植生存率;校正病因、年龄、升压药支持、INR、King's College Criteria及倾向评分后,分子吸附再循环系统OR 1.90(95%CI 1.07-3.39,P=0.030)。
  • 敏感性分析:模型2(校正病因和倾向评分)OR 1.86(95%CI 1.05-3.31,P=0.033);模型3(主模型+机械通气+3/4级肝性脑病)OR 1.91(95%CI 1.07-3.41,P=0.029)。
  • 对乙酰氨基酚亚组(n=51)治疗前后平均动脉压92.0 vs 78.0 mm Hg、肌酐77.0 vs 128.2 µmol/L、乳酸2.3 vs 4.3 mmol/L、血氨98.0 vs 136.0 µmol/L,P≤0.002。
  • 非对乙酰氨基酚亚组(n=53)治疗前后胆红素205.2 vs 251.4 µmol/L、肌酐83.1 vs 133.5 µmol/L、血氨111.5 vs 140.0 µmol/L,P≤0.022。
  • 原文未提及关键次要终点(如无移植生存以外的临床结局)及不良事件。

证据类型、等级与局限

  • 证据类型:多中心倾向评分匹配回顾性队列研究。
  • 局限:回顾性设计、非随机对照、对照来自注册库、样本量有限(分子吸附再循环系统组104例),存在未测量混杂可能。

对床旁实践的改变

  • 原文提示对急性肝衰竭患者使用分子吸附再循环系统与21天无移植生存率升高相关,尤其对乙酰氨基酚相关急性肝衰竭患者血流动力学和生化指标改善更明显,但回顾性设计不能确立因果,不能据此将其作为标准推荐。
  • 原文未提及适用与不适用人群的具体标准,临床决策需结合原文未覆盖的个体情况。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: The molecular adsorbent recirculating system removes water-soluble and albumin-bound toxins and may be beneficial for acute liver failure patients. We compared the rates of 21-day transplant-free survival in acute liver failure patients receiving molecular adsorbent recirculating system therapy and patients receiving standard medical therapy.

DESIGN: Propensity score-matched retrospective cohort analysis.

SETTING: Tertiary North American liver transplant centers.

PATIENTS: Acute liver failure patients receiving molecular adsorbent recirculating system at three transplantation centers (n = 104; January 2009-2019) and controls from the U.S. Acute Liver Failure Study Group registry.

INTERVENTIONS: Molecular adsorbent recirculating system treatment versus standard medical therapy (control).

MEASUREMENTS AND MAIN RESULTS: One-hundred four molecular adsorbent recirculating system patients were propensity score-matched (4:1) to 416 controls. Using multivariable conditional logistic regression adjusting for acute liver failure etiology (acetaminophen: n = 248; vs nonacetaminophen: n = 272), age, vasopressor support, international normalized ratio, King's College Criteria, and propensity score (main model), molecular adsorbent recirculating system was significantly associated with increased 21-day transplant-free survival (odds ratio, 1.90; 95% CI, 1.07-3.39; p = 0.030). This association remained significant in several sensitivity analyses, including adjustment for acute liver failure etiology and propensity score alone ("model 2"; molecular adsorbent recirculating system odds ratio, 1.86; 95% CI, 1.05-3.31; p = 0.033), and further adjustment of the "main model" for mechanical ventilation, and grade 3/4 hepatic encephalopathy ("model 3"; molecular adsorbent recirculating system odds ratio, 1.91; 95% CI, 1.07-3.41; p = 0.029). In acetaminophen-acute liver failure (n = 51), molecular adsorbent recirculating system was associated with significant improvements (post vs pre) in mean arterial pressure (92.0 vs 78.0 mm Hg), creatinine (77.0 vs 128.2 µmol/L), lactate (2.3 vs 4.3 mmol/L), and ammonia (98.0 vs 136.0 µmol/L; p ≤ 0.002 for all). In nonacetaminophen acute liver failure (n = 53), molecular adsorbent recirculating system was associated with significant improvements in bilirubin (205.2 vs 251.4 µmol/L), creatinine (83.1 vs 133.5 µmol/L), and ammonia (111.5 vs 140.0 µmol/L; p ≤ 0.022 for all).

CONCLUSIONS: Treatment with molecular adsorbent recirculating system is associated with increased 21-day transplant-free survival in acute liver failure and improves biochemical variables and hemodynamics, particularly in acetaminophen-acute liver failure.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. MacDonald AJ, Subramanian RM, Olson JC, et al. Use of the Molecular Adsorbent Recirculating System in Acute Liver Failure: Results of a Multicenter Propensity Score-Matched Study. Crit Care Med. 2022. PMID: 34259656. doi:10.1097/CCM.0000000000005194

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。